Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Excessive Early Death after Intensive Chemotherapy for Acute Myeloid Leukemia Occurs in Patients over 65 Years with High Co-Morbidity, and in Patients over 50 Years with High Co-Morbidity When Postponed Early Death Is Included

J Claire Sinigaglia, Liesbeth C de Wreede, PhD, Hendrik Veelken, MD PhD, Peter A. Von Dem Borne, MD PhD

Blood (2017) 130 (Supplement 1): 1316.

https://doi.org/10.1182/blood.V130.Suppl_1.1316.1316

Published: 2017

Journal Articles

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

Peter A. Von Dem Borne, MD, PhD, Constantijn J.M. Halkes, MD, PhD, Erik W.A. Marijt, MD, PhD, Sabina Kersting, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, J.Hendrik Veelken, MD, PhD

Blood (2012) 120 (21): 3085.

https://doi.org/10.1182/blood.V120.21.3085.3085

Published: 2012

Journal Articles

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD, Judith Olde Wolbers, Esther M van Egmond, Peter A. Von Dem Borne, MD, PhD, Erik W.A.F. Marijt, MD, PhD, J.H.Frederik Falkenburg, MD, PhD

Blood (2010) 116 (21): 2330.

https://doi.org/10.1182/blood.V116.21.2330.2330

Published: 2010

Journal Articles

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Tom Lodewyck, MD, Machteld Oudshoorn, PhD, Bronno van der Holt, PhD, Eefke Petersen, MD, PhD, Eric Spierings, PhD, Peter A. Von Dem Borne, MD, PhD, Anton Schattenberg, MD, PhD, Wil Allebes, PhD, Ellen Meijer, MD, PhD, Marlies Groenendijk-Sijnke, Lucia Duinhouwer, Roelof Willemze, MD, PhD, Leo F. Verdonck, MD, PhD, Bob Lowenberg, MD, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 1196.

https://doi.org/10.1182/blood.V114.22.1196.1196

Published: 2009

Journal Articles

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD PhD, Roelof Willemze, MD PhD, J.H. Frederik Falkenburg, MD PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 2454.

https://doi.org/10.1182/blood.V114.22.2454.2454

Published: 2009

Journal Articles

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

Boris van der Zouwen, MD, Alwine B. Kruisselbrink, Peter A. Von Dem Borne, MD, PhD, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD, Inge Jedema, PhD

Blood (2009) 114 (22): 3552.

https://doi.org/10.1182/blood.V114.22.3552.3552

Published: 2009

Journal Articles

SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

Pleun Hombrink, MSc, Sine R Hadrup, PhD, Arne Bakker, PhD, J.H. Frederik Falkenburg, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Ton N Schumacher, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2008) 112 (11): 814.

https://doi.org/10.1182/blood.V112.11.814.814

Published: 2008

Journal Articles

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, MD, PhD, Peter A. Von Dem Borne, MD, PhD, Gerard M.J. Bos, MD, PhD, Sandra Croockewit, MD, PhD, Jan J. Cornelissen, MD, PhD, Marinus van Oers, Martyn Ronald Schaafsma, Harm Sinnige, MD, PhD, Michel Delforge, MD, PhD, Okke de Weerdt, Pierre W Wijermans, Shulamiet Wittebol, MD, PhD, Edo Vellenga, MD, PhD, Asiong Jie, Henriette Berenschot, MD, PhD, Marinus Marwijk-kooy, MD, PhD, Pieter Sonneveld, MD, PhD

Blood (2008) 112 (11): 157.

https://doi.org/10.1182/blood.V112.11.157.157

Published: 2008

Journal Articles

Donor Lymphocyte Infusion for Mixed Chimerism or Residual Disease after Reduced-Intensity T Cell Depleted Stem Cell Transplantation Results in Conversion to Full Donor Chimerism Combined with Graft Versus Tumor Responses and Limited GVHD.

Peter A. von dem Borne, MD, PhD, Ingrid Starrenburg, Erik W.A. Marijt, Stijn Halkes, J.H. Frederik Falkenburg, Roel Willemze

Blood (2007) 110 (11): 1652.

https://doi.org/10.1182/blood.V110.11.1652.1652

Published: 2007

Journal Articles

Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.

Erik W.A. Marijt, MD, PhD, Peter A. Von Dem Borne, MD PhD, Renee M.Y. Barge, MD PhD, Piette P. Deutz, M. Floor Beaumont, C.W.J. Ingrid Starrenburg, Willem E. Fibbe, MD PhD, Roelof Willemze, MD PhD, J.H. Frederik Falkenburg, MD PhD

Blood (2006) 108 (11): 3674.

https://doi.org/10.1182/blood.V108.11.3674.3674

Published: 2006

NARROW

Excessive Early Death after Intensive Chemotherapy for Acute Myeloid Leukemia Occurs in Patients over 65 Years with High Co-Morbidity, and in Patients over 50 Years with High Co-Morbidity When Postponed Early Death Is Included

Effectiveness of a Strategy to Proceed to Allogeneic Stem Cell Transplantation in All Elderly AML Patients Treated with Intensive Chemotherapy: Only Patients in Complete Remission After First Induction Show Long Term Survival.

Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells

Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.

Potent Alloreactive Effector T Cells Cause Limited Damage to Non-Hematopoietic Tissues Under Non-Inflammatory Conditions, Despite Proper Expression of the Relevant Target Antigens.

Collateral Damage: a Mechanism for Hematopoiesis-Restricted Mhag-Specific T Cells to Play a Role in the Effector Phase of GvHD.

SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens

Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM)

Donor Lymphocyte Infusion for Mixed Chimerism or Residual Disease after Reduced-Intensity T Cell Depleted Stem Cell Transplantation Results in Conversion to Full Donor Chimerism Combined with Graft Versus Tumor Responses and Limited GVHD.

Donor Lymphocyte Infusion (DLI) for Mixed Chimerism 6 Months after T Cell Depleted Allogeneic Stem Cell Transplantation (TCD alloSCT) May Prevent Relapse.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only